Hutch News

Hutch News

Stories tagged 'John Thompson'

7 skin cancer myths — debunked

Experts take on base tans and other ‘complete baloney’ standing in the way of skin health

Aug. 2, 2017 | By Susan Keown / Fred Hutch News Service

From indoor tanning to sunscreen use: Lower your risk of skin cancer by confronting these myths head on.

View story >

Good News at Fred Hutch

Celebrating faculty and staff achievements

Nov. 14, 2016

Good News: Drs. Harmit Malik, Jesse Bloom win ASM awards; Fred Hutch team launches personalized anticancer vaccine project

View story >

Cancer Immunotherapy Trials Network selects member sites

Center-based initiative announces 27 institutional partners in national research effort to accelerate clinical trials of promising cancer immunotherapies

April 11, 2011

Research institutions at 27 sites across North America have been selected as part of the Cancer Immunotherapy Trials Network, based at the Fred Hutchinson Cancer Research Center. A new initiative in immunotherapy, CITN unites top academic immunologists to conduct multicenter research on therapies that boost patients’ own immune systems to fight cancer.

View story >

SCCA opens Northwest’s first academic phase 1 Clinical Trials Unit

Facility will increase earlier access to promising new drugs

June 14, 2010 | By Dean Forbes

A dedicated space for cancer patients volunteering to be part of first-phase clinical drug studies has opened at the Seattle Cancer Care Alliance. The phase 1 Clinical Trials Unit is the Pacific Northwest’s first such academic-based program and serves the Fred Hutchinson/University of Washington Cancer Consortium.

View story >

Encouraging results for renal-cell cancer trial

An international team of investigators report progression-free survival in patients treated with IL-21 combined with Nexavar after failure of prior therapy

June 1, 2009

Researchers at ZymoGenetics, Inc. announced positive final results from a phase 2 clinical trial in patients receiving second or third-line therapy for advanced renal cell carcinoma with the combination of recombinant Interleukin 21 (IL-21) and Nexavar® (sorafenib) tablets. The combination demonstrated considerable clinical benefit, with an overall response rate of 21 percent, a disease-control rate of 82 percent, and progression-free survival of 5.7 months in this heavily pretreated population.

View story >

John Thompson named director Consortium's phase I trials

Oct. 1, 2007

View story >

(RSS feeds are best viewed in browsers other than Chrome)

Editor's Picks


Support our quest for cures

Story Archive


Magazine Archive
Back issues of Hutch Magazine

Financial Reporting
Fiscal highlights & Annual Reports

Science Spotlight
Monthly review of Center-authored papers

Fred Hutch News

        Get updates via email.